LAUSR

In reply: In this commentary, we respond to Dr Vogel and Dr Dürstelar's letter to our original piece "A Plea From People Who Use Drugs to Clinicians: New Ways to Initiate Buprenorphine Are Urgently Needed in the Fentanyl Era" published in this journal in July to August 2022. We agree with much of their comment on buprenorphine initiation and point to the need for rapid expansion of medication for opioid use disorder (OUD) treatments here in the United States. It is critical to understand the context of current buprenorphine and methadone access. We point out how the treatment of OUD with agonist therapy remains limited to methadone or buprenorphine despite an increasingly toxic drug supply within our particular legal and regulatory environment and call for urgent research and pilot programs to trial additional agonist therapies for those with opioid OUD as well as regulatory changes to increase access to both methadone and buprenorphine.